Transdermal Delivery of PTEN mRNA via Hyaluronated Lipid Nanoparticles: A Novel Approach for Melanoma Immunotherapy

Study Background and Research Question

Melanoma, the most aggressive skin cancer, poses significant clinical challenges due to its high metastatic potential and frequent resistance to existing immunotherapies. Immune checkpoint inhibitors (ICIs) have revolutionized treatment, but less than half of patients experience lasting benefits, often due to tumor adaptation and immune evasion. Loss of the phosphatase and tensin homolog (PTEN) gene—a critical tumor suppressor—has been identified as a central mechanism behind immune resistance and tumor progression. PTEN functions as a negative regulator of the PI3K/Akt signaling pathway, and its loss is implicated in unchecked melanoma cell proliferation, reduced apoptosis, and diminished T cell infiltration. Therefore, restoring PTEN activity in tumor cells represents a promising strategy to re-engage antitumor immunity and improve therapeutic outcomes. The reference study (Kim et al., 2026) addresses a key research question: Can transdermal, non-invasive administration of PTEN mRNA using a targeted nanoparticle system restore tumor suppressor function and enhance melanoma immunotherapy?

Key Innovation from the Reference Study

The principal innovation lies in the development of a hyaluronate-conjugated lipid nanoparticle (HA-LNP) system for encapsulating and delivering tumor suppressor gene mRNA—specifically, PTEN mRNA—through the skin. Unlike conventional lipid nanoparticles that use PEGylation for stability (which can induce immunogenicity and hypersensitivity), this study introduces HA-dimyristoyl glycerol (HA-DMG) as an amphiphilic lipid component. This modification integrates hyaluronate directly into the LNP structure, enhancing both particle stability and CD44-mediated tumor targeting. Crucially, the HA-LNP platform enables non-invasive, localized mRNA delivery, targeting CD44-expressing tumor cells and skin-resident immune cells, and bypassing some of the systemic toxicity and delivery limitations observed with viral vectors or DNA-based gene therapies.

Methods and Experimental Design Insights

Kim et al. engineered the HA-LNPs by self-assembling lipids with HA-DMG, ensuring stable and uniform incorporation of HA within the nanoparticle bilayer. This amphiphilic design replaced PEG-lipids, mitigating risks associated with PEG-induced anaphylaxis and immunogenicity. The resulting nanoparticles efficiently encapsulated large mRNA payloads, including PTEN mRNA, and displayed HA moieties on their surface for enhanced biocompatibility and selective uptake by CD44-positive melanoma cells.

For in vitro studies, PTEN mRNA@HA-LNPs were incubated with melanoma cell lines to assess PTEN restoration, cell viability, and immunogenic cell death (ICD). In vivo, the nanoparticles were topically applied to melanoma-bearing mice, with tumor growth inhibition, immune activation, and toxicity profiles monitored over time. Advanced imaging and immunohistochemistry confirmed nanoparticle penetration, tumor targeting, and PTEN expression restoration.

Protocol Parameters

• HA-LNP Formulation: Incorporation of HA-DMG (hyaluronate-dimyristoyl glycerol) into lipid nanoparticle self-assembly to replace PEG-lipids and display HA on the surface.
• mRNA Payload: Use of in vitro transcribed, chemically modified human PTEN mRNA for encapsulation.
• Transdermal Application: Topical administration of PTEN mRNA@HA-LNP to the tumor-bearing skin, enabling penetration and uptake by CD44+ cells.
• Immunogenicity Assays: Assessment of ICD markers, immune cell infiltration (CD8+ T cells), and cytokine profiles in treated tumors.
• In Vivo Monitoring: Tumor size, animal weight, and histological analysis to evaluate efficacy and safety.

Core Findings and Why They Matter

The study demonstrates that HA-LNPs efficiently encapsulate and deliver PTEN mRNA across the skin barrier, leading to robust restoration of PTEN expression in melanoma cells both in vitro and in vivo. Key findings include:

• Restoration of Tumor Suppressor Function: PTEN mRNA@HA-LNP treatment reversed PTEN loss in tumor cells, suppressing the PI3K/Akt signaling pathway and reducing melanoma cell viability.
• Induction of Immunogenic Cell Death: Treated melanoma cells exhibited increased markers of ICD, facilitating antigen presentation and immune activation.
• Enhanced Antitumor Immunity: In murine models, topical application led to increased T cell infiltration, reduced tumor growth, and improved immune-mediated tumor clearance, with minimal toxicity (see study).
• Superior Biocompatibility: HA-LNPs showed improved safety compared to conventional PEG-LNPs, with no signs of systemic toxicity or adverse immune reactions.

These results collectively support the feasibility of localized, mRNA-based cancer immunotherapy as a means to overcome immune evasion and checkpoint inhibitor resistance in melanoma.

Comparison with Existing Internal Articles

Several recent summaries offer context and complementary insights:

• The article "EZ Cap™ Human PTEN mRNA: Redefining Tumor Suppressor Gene Delivery" explores the biochemical advantages of Cap 1 and poly(A) tail modifications for tumor suppressor gene mRNA, emphasizing their role in enhancing translation and reducing innate immune activation. These features are critical for maximizing PTEN expression following HA-LNP-mediated delivery.
• Studies such as "Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Immunotherapy" and "Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Therapy" echo the reference study's findings, highlighting the ability of HA-LNPs to restore PTEN expression in melanoma models, enhance immune activation, and inhibit tumor growth. These articles reinforce the translational potential of localized mRNA delivery approaches for cancer research and gene therapy research.

Together, these internal resources and the reference study illustrate a consistent shift toward mRNA transfection and expression using advanced nanoparticle platforms, with attention to stability enhancement via Cap 1 structure and poly(A) tail modifications.

Limitations and Transferability

While the reference study presents compelling evidence for the efficacy of HA-LNP-mediated PTEN mRNA delivery, certain limitations should be considered. The research was primarily conducted in murine melanoma models, and while the skin’s abundance of CD44-expressing cells favors transdermal targeting, the degree of penetration and therapeutic response in human skin and tumors may differ. The scalability and manufacturability of HA-DMG-conjugated LNPs at clinical grade require further optimization. Additionally, mRNA stability, although improved by chemical modification and nanoparticle encapsulation, remains sensitive to enzymatic degradation and requires rigorous handling protocols. The transient nature of mRNA expression, while reducing risk of genomic integration, may necessitate repeated dosing for sustained therapeutic effect.

Research Support Resources

Researchers wishing to replicate or extend these findings can utilize high-quality, in vitro transcribed PTEN mRNA preparations. For example, EZ Cap™ Human PTEN mRNA (SKU R1025) from APExBIO features a Cap 1 structure and poly(A) tail, supporting enhanced mRNA stability and translation efficiency, as detailed in the internal article. Pairing such tumor suppressor gene mRNA with optimized nanoparticle systems like HA-LNPs enables advanced applications in cancer research, particularly for investigating PI3K/Akt signaling pathway modulation, localized immunotherapy, and gene therapy research workflows.